Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | FPR2 | P25090 | 8/20 | 0.44 |
| ▸ | FPR3 | P25089 | 6/20 | 0.44 |
| ▸ | DRD2 | P14416 | 2/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | CCR1 | P32246 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29691893 | 0.97 | RORC (0.48) | RORCMEN1KMT2AFPR2FPR3 | |
| SCHEMBL1430196 | 0.92 | RORC (0.50) | RORCMEN1KMT2AFPR2FPR3 | |
| SCHEMBL19462827 | 0.92 | RORC (0.50) | RORCMEN1KMT2AFPR2FPR3 | |
| SCHEMBL1199600 | 0.92 | RORC (0.51) | RORCFPR2FPR3DRD2CA12 | |
| SCHEMBL21836954 | 0.85 | RORC (0.48) | RORCFPR2FPR3CA12CA1 | |
| SCHEMBL652370 | 0.85 | MEN1 (0.58) | MEN1KMT2ADRD2CA12CA1 | |
| SCHEMBL1239091 | 0.85 | RORC (0.48) | RORCMEN1KMT2ADRD2CCR1 | |
| SCHEMBL3695939 | 0.84 | RORC (0.54) | RORCFPR2FPR3DRD2CA12 | |
| SCHEMBL15595091 | 0.84 | TSHR (0.53) | MEN1KMT2AGPR119 | |
| SCHEMBL16874679 | 0.84 | ALDH1A1 (0.51) | MEN1KMT2AMAPTGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4434522-A2 | HETEROCYCLIC P2Y14 RECEPTOR ANTAGONISTS | The United States of America, as represented by the Secretary, Department of Health and Human Services (US) | 2024-09-25 | — | — | EP | disclosed |
| US-20240150290-A1 | HETEROCYCLIC P2Y14 RECEPTOR ANTAGONISTS | THE UNITED STATES OF AMERICA,AS REPRESENTED BY THE SECRETARY,DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2024-05-09 | — | — | US | disclosed |
| EP-4277895-A1 | HETEROCYCLIC P2Y 14 RECEPTOR ANTAGONISTS | The United States of America, as represented by the Secretary, Department of Health and Human Services (US) | 2023-11-22 | — | — | EP | disclosed |
| CN-116964034-A | Heterocyclic ring P2Y 14 Receptor antagonists | 美国卫生和人力服务部 | 2023-10-27 | — | — | CN | disclosed |
| WO-2022155037-A1 | HETEROCYCLIC P2Y 14 RECEPTOR ANTAGONISTS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2022-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240150290-A1 | HETEROCYCLIC P2Y14 RECEPTOR ANTAGONISTS | P2RY14, P2RY1, P2RY11 | RORC 1027/4885MEN1 2957/4885KMT2A 3669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.